Immunotoxin Therapy in Treating Patients With Advanced Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed malignancy, including one of the following: * Malignant mesothelioma * Ovarian epithelial carcinoma (mucinous or nonmucinous), including primary peritoneal or fallopian tube carcinoma * Tumors that may have originated in the bowel (e.g., appendiceal carcinoma) and involve the ovary * Ovarian cancers of other histology are eligible provided they express mesothelin * Pancreatic cancer * Squamous cell lung cancer * Squamous cell cancer of the head and neck * Squamous cell cancer of the cervix * Recurrent unresectable disease after prior standard anticancer therapy that was expected to prolong survival and improve quality of life OR unwilling to receive standard anticancer therapy * At least 30% of initial or recurrent tumor cells positive (at least 1+) for mesothelin by immunohistochemistry * Measurable or evaluable disease * No known CNS or spinal cord involvement * No clinically significant pericardial effusion PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * At least 12 weeks Hematopoietic: * Absolute neutrophil count at least 1,000/mm\^3 * Platelet count at least 75,000/mm\^3 Hepatic: * Bilirubin no greater than upper limit of normal (ULN) * AST and ALT no greater than 2.5 times ULN * Albumin at least 3.0 g/dL * Hepatitis B and C negative Renal: * Creatinine no greater than ULN OR * Creatinine no greater than 2.0 mg/dL if creatinine clearance a…